IHD subjects who are taking rosvastatin 2.5mg or atorvastatin 10mg more than 3 months and whose LDL-C is >
Conditions
Interventions
Combination therapy wiht ezetimibe 10mg
Increase in dose for both statins.
Sponsors
Yokohama City University Graduate School of Medicine, Department of Medicine and Cardio-renal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects who has a past history of coronary heart diseases with LDL-C >100mg/dl and who took rosuvastatin 2.5mg or atorvastatin 10mg more than 3 months. Age from 20 to 80. Gender free.
Exclusion criteria
Exclusion criteria: 1)Subjects with hypersentivity for ezetimibe or staitns. 2)triglyceride>500mg/dl 3)liver dysfunction (AST>twice as much as the upperlimit of the facilities. 4)kidney dysfunction (serum Cr>2.0mg/dl) 5)secondary hyperlipidemia or drug induced hyperlipidemia 6)unstabel angina, myocardial infarction, coronary bypass surgery, brain infarction within 3 months. 7)pregnancy, lactation, possible pregnancy 8)According to the attending physician`s judgements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, cholesterol absorption marker, cholesterol synthesis marker, glucose metabolic marker, inflammation marker, other laboratory findings. | — |
Countries
Japan
Contacts
Public ContactKazuaki Uchino
Department of Medicine and Cardio-renal Medicine Department of Medicine and Cardio-renal Medicine
Outcome results
None listed